Bayer AG and Evotec AG have recently struck a second collaboration, this time in kidney disease, on the back of their successful discovery and development partnership looking at new drug candidates for women's health indications. Bayer's head of development for pharmaceuticals, Dr Joerg Moeller, and Evotec chief, Dr Werner Lanthaler, told Scrip more about their "modern" setup and how fixed project endings help to eradicate development bottlenecks.
In Oct. 2012 Bayer and Evotec entered into a five-year multi-target strategic alliance to identify three small molecule clinical candidates for the treatment of endometriosis. Four years since signing the pact, the pair have discovered five preclinical assets and identified their first compound to take into the clinic
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?